SRR934931
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 80.71616294349539
- age_years
- 48
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- CHOLESTEROL_HOMEOSTASIS+0.514
- MTORC1_SIGNALING+0.494
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.477
- MYC_TARGETS_V1+0.465
- PROTEIN_SECRETION+0.461
- OXIDATIVE_PHOSPHORYLATION+0.426
- UNFOLDED_PROTEIN_RESPONSE+0.423
- E2F_TARGETS+0.418
- INTERFERON_ALPHA_RESPONSE+0.407
- FATTY_ACID_METABOLISM+0.392
Top 10 suppressed
- KRAS_SIGNALING_DN-0.493
- HEDGEHOG_SIGNALING-0.369
- PANCREAS_BETA_CELLS-0.350
- SPERMATOGENESIS-0.307
- APICAL_SURFACE-0.276
- MYOGENESIS-0.166
- ESTROGEN_RESPONSE_EARLY-0.074
- ESTROGEN_RESPONSE_LATE-0.027
- APICAL_JUNCTION-0.022
- WNT_BETA_CATENIN_SIGNALING+0.033
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 54B7F258-FE9A-4EFE-87FB-465D587B1170 | — | — | 0.930 |
| 2 | MNG485 | — | — | 0.924 |
| 3 | 33800B09-6DCC-4BE8-891C-5F34ADAC65B3 | — | — | 0.923 |
| 4 | 769432C5-4BFD-4689-8F43-467010292448 | — | — | 0.922 |
| 5 | BB96C5BA-CA50-40B4-B22A-3FCFE46AB11C | — | — | 0.922 |
| 6 | 7876A884-F031-42AB-ADC0-89589760FB6B | — | — | 0.921 |
| 7 | 95286AA4-B357-41FE-8051-3BD3EBE93885 | — | — | 0.919 |
| 8 | 6D1D9992-DA2B-419A-A80A-9EBCDA831754 | — | — | 0.919 |
| 9 | 94640BD8-E1D9-482D-A597-4790F6EEA6B7 | — | — | 0.918 |
| 10 | 8730AABF-0720-4754-82B0-722150A485B8 | — | — | 0.917 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 41 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| CHOLESTEROL_HOMEOSTASIS | 0.514 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.494 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.477 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.465 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.461 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.426 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.423 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.418 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.407 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.392 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.374 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.371 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.370 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.364 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.353 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.337 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.329 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.329 | Inavolisib | — uncovered |
| PEROXISOME | 0.293 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.288 | Inavolisib | — uncovered |